ライブラリ登録: Guest
Critical Reviews™ in Oncogenesis

年間 4 号発行

ISSN 印刷: 0893-9675

ISSN オンライン: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

The c-erbB-2 Protein in Oncogenesis: Molecular Structure to Molecular Epidemiology

巻 5, 発行 2-3, 1994, pp. 313-329
DOI: 10.1615/CritRevOncog.v5.i2-3.100
Get accessGet access

要約

The c-erbB-2 (HER-2, neu) oncogene has been implicated frequently in many human tumors. This oncogene codes for a 185-kDa protein that functions as a transmembrane growth factor receptor. Overexpression of the normal protein or point mutations in the transmembrane domain of the protein have been shown to have a transforming effect. Molecular structure studies of the transmembrane domain provide a plausible explanation for this transforming effect in both cases and relate this to the process of receptor dimerization in the membrane, degradation of the protein with release of the extracellular domain (ECD) into the extracellular environment, and aberrant signal transduction. The release of the ECD into the extracellular environment provides a potential biomarker for the study of signal transduction at the molecular level in vivo. The ECD can be quantitated immunologically in the serum of individuals with cancers associated with p185 overexpression and in individuals at risk for the development of such cancers and can be used to distinguish these individuals from normal, healthy controls. Identification of such individuals by their serum ECD levels combined with specific chemotherapeutic/ chemoprophylactic interventions could allow for improvement treatment and prevention of c-erbB-2-related cancers.

によって引用された
  1. Brandt-Rauf Paul W., Pincus Matthew R., Monaco Regina, Conformation of the transmembrane domain of the c-erbB-2 oncogene-encoded protein in its monomeric and dimeric states, Journal of Protein Chemistry, 14, 1, 1995. Crossref

  2. Chung Daniel C., Podolsky Daniel K., Cellular Growth and Neoplasia, in Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 2010. Crossref

  3. Rayson Daniel, Erlichman Charles, Suman Vera J., Roche Patrick C., Wold Lester E., Ingle James N., Donohue John H., Molecular markers in male breast carcinoma, Cancer, 83, 9, 1998. Crossref

  4. Pincus Matthew R., Brandt-Rauf Paul W., Bluth Martin H., Bowne Wilbur B., Oncoproteins and Early Tumor Detection, in Henry's Clinical Diagnosis and Management by Laboratory Methods, 2011. Crossref

  5. Garnier Norbert, Genest Daniel, Duneau Jean Pierre, Genest Monique, Molecular modeling of c-erbB2 receptor dimerization: Coiled-coil structure of wild and oncogenic transmembrane domains—Stabilization by interhelical hydrogen bonds in the oncogenic form, Biopolymers, 42, 2, 1997. Crossref

  6. Ayat Hoda, Burrone Oscar R., Sadghizadeh Majid, Jahanzad Eissa, Rastgou Nasrin, Moghadasi Sarrira, Arbabi Mehdi, Isolation of scFv antibody fragments against HER2 and CEA tumor antigens from combinatorial antibody libraries derived from cancer patients, Biologicals, 41, 6, 2013. Crossref

  7. Mazouni Chafika, Hall Angeline, Broglio Kristine, Fritsche Herbert, Andre Fabrice, Esteva Francisco J., Hortobagyi Gabriel N., Buzdar Aman U., Pusztai Lajos, Cristofanilli Massimo, Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy, Cancer, 109, 3, 2007. Crossref

  8. Lee Jung-Sun, Min Won Ki, Park Eun Hwa, Lim Woo-Sung, Choi Sung-Lim, Son Byung-Ho, Kim Sung-Bae, Ahn Jin-Hee, Ahn Sei-Hyun, Correlation between the Her-2/neu Status as Determined by Immunohistochemical Analysis and the Serum Her-2/neu Concentration as Determined by the Use of ADVIA Cencaur® Automated Immunoassay in Breast Cancer Patients, Journal of Breast Cancer, 11, 3, 2008. Crossref

  9. MEYSKENS FRANK L., Development of Bowman-Birk Inhibitor for Chemoprevention of Oral Head and Neck Cancer, Annals of the New York Academy of Sciences, 952, 1, 2001. Crossref

  10. Tambo Mitsuhiro, Higashihara Eiji, Terado Yuichi, Nutahara Kikuo, Okegawa Takatsugu, Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer, International Journal of Urology, 16, 4, 2009. Crossref

  11. Abdel Salam I., Gaballa H. E., Abdel Wahab N., Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation, Medical Oncology, 26, 2, 2009. Crossref

  12. Iqbal Nida, Iqbal Naveed, Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications, Molecular Biology International, 2014, 2014. Crossref

  13. Vijayanathan Veena, Thomas Thresia, Sigal Leonard H., Thomas T.J., Direct Measurement of the Association Constant of HER2/neuAntisense Oligonucleotide to Its Target RNA Sequence Using a Molecular Beacon, Antisense and Nucleic Acid Drug Development, 12, 4, 2002. Crossref

  14. Lüftner Diana, Lüke Claudia, Possinger Kurt, Serum HER-2/neu in the management of breast cancer patients, Clinical Biochemistry, 36, 4, 2003. Crossref

  15. Sun Zijia, Shi Yaqin, Shen Yan, Cao Lulu, Zhang Wenwen, Guan Xiaoxiang, Analysis of different HER ‐2 mutations in breast cancer progression and drug resistance , Journal of Cellular and Molecular Medicine, 19, 12, 2015. Crossref

  16. Maddry Joseph A., Kussner Conrad, Truss Jackie W., Niwas Shri, Lucile White E., Kwong Cecil D., Inhibition of the her2 tyrosine kinase and characterization of a hydrophobic site near the nucleotide binding domain, Bioorganic & Medicinal Chemistry Letters, 7, 16, 1997. Crossref

  17. Wilkman Tommy S.E., Hietanen Jarkko H.P., Maimström Maria J., Konttinen Yrjö T., Immunohistochemical analysis of the oncoprotein c-erbB-2 expression in oral benign and malignant lesions, International Journal of Oral and Maxillofacial Surgery, 27, 3, 1998. Crossref

  18. Fosså Alexander, Lilleby Wolfgang, Fosså Sophie D., Gaudernack Gustav, Torlakovic Goran, Berner Aasmund, Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy, International Journal of Cancer, 99, 1, 2002. Crossref

  19. Tomasz Kręcicki, Michał Jeleń, Mari , C-erbB-2 Immunostaining in Laryngeal Cancer, Acta Oto-Laryngologica, 119, 3, 1999. Crossref

  20. Croal B.L., Mitchell I.D.C., Mutch W.J., Dickie A., Cohen N., Ross I.S., Serum HER-2/neu Extracellular Domain Levels in Men Presenting with Suspected Prostate Cancer, UroOncology, 2, 2, 2002. Crossref

  21. Xu Ruliang, Perle Mary Ann, Inghirami Giorgio, Chan Wai, Delgado Yara, Feiner Helen, Amplification of Her-2/neu Gene in Her-2/neu-Overexpressing and -Nonexpressing Breast Carcinomas and Their Synchronous Benign, Premalignant, and Metastatic Lesions Detected by FISH in Archival Material, Modern Pathology, 15, 2, 2002. Crossref

  22. Lüftner D., Cheli C., Mickelson K., Sampson E., Possinger K., ADVIA Centaur® Her-2/Neu Shows Value in Monitoring Patients with Metastatic Breast Cancer, The International Journal of Biological Markers, 19, 3, 2004. Crossref

  23. Brandt-Rauf P W, Biomarkers of gene expression: growth factors and oncoproteins., Environmental Health Perspectives, 105, suppl 4, 1997. Crossref

  24. Carney Walter P., The Emerging Role of Monitoring Serum HER-2/neuOncoprotein Levels in Women with Metastatic Breast Cancer, Laboratory Medicine, 34, 1, 2003. Crossref

  25. Linderholm Barbro, Lindahl Thomas, Öhd John, Bergh Jonas, Cellular and Tissue Markers in Solid Tumors, in Principles of Molecular Oncology, 2004. Crossref

  26. Sareyeldin Rasha M., Gupta Ishita, Al-Hashimi Israa, Al-Thawadi Hamda A., Al Farsi Halema F., Vranic Semir, Al Moustafa Ala-Eddin, Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer, Cancers, 11, 5, 2019. Crossref

  27. Carney Walter P, Neumann Rainer, Lipton Allan, Leitzel Kim, Ali Suhail, Price Christopher P, Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer, Clinical Chemistry, 49, 10, 2003. Crossref

  28. Payne Robert C, Allard Jeffrey W, Anderson-Mauser Linda, Humphreys John D, Tenney Donald Y, Morris David L, Automated Assay for HER-2/neu in Serum, Clinical Chemistry, 46, 2, 2000. Crossref

  29. Eppenberger-Castori Serenella, Klingbiel Dirk, Ruhstaller Thomas, Dietrich Daniel, Rufle Daniel Alexander, Rothgiesser Karin, Pagani Olivia, Thürlimann Beat, Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99, BMC Cancer, 20, 1, 2020. Crossref

  30. Shiravi Fariba, Mohammadi Mehdi, Golsaz-Shirazi Forough, Bahadori Tannaz, Judaki Mohammad Ali, Fatemi Forough, Zare Hengameh Ahmadi, Haghighat Farzaneh Notash, Mobini Maryam, Jeddi-Tehrani Mahmood, Amiri Mohammad Mehdi, Shokri Fazel, Potent synergistic anti-tumor activity of a novel humanized anti-HER2 antibody hersintuzumab in combination with trastuzumab in xenograft models, Investigational New Drugs, 39, 3, 2021. Crossref

  31. Seyedmirzaei Homa, Keshavarz-Fathi Mahsa, Razi Sepideh, Gity Masoumeh, Rezaei Nima, Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2), Journal of Oncology Pharmacy Practice, 27, 5, 2021. Crossref

  32. Al-Share Bayan, Hammad Nour, Diab Maria, Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy, Cancer and Metastasis Reviews, 40, 1, 2021. Crossref

  33. Joshi Bishnu P., Zhou Juan, Pant Asha, Duan Xiyu, Zhou Quan, Kuick Rork, Owens Scott R., Appelman Henry, Wang Thomas D., Design and Synthesis of Near-Infrared Peptide for in Vivo Molecular Imaging of HER2, Bioconjugate Chemistry, 27, 2, 2016. Crossref

  34. Armstrong William B., Taylor Thomas H., Kennedy Ann R., Melrose Raymond J., Messadi Diana V., Gu Mai, Le Anh D., Perloff Marjorie, Civantos Francisco, Goodwin William Jarrard, Wirth Lori J., Kerr Alexander Ross, Meyskens Frank L., Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial, Cancer Prevention Research, 6, 5, 2013. Crossref

  35. Brandt-Rauf Paul W., Pincus Matthew R., Molecular Markers of Carcinogenesis, Pharmacology & Therapeutics, 77, 2, 1998. Crossref

  36. Zannoni Gian Franco, Bragantini Emma, Castiglione Francesca, Fassan Matteo, Troncone Giancarlo, Inzani Frediano, Pesci Anna, Santoro Angela, Fraggetta Filippo, Current Prognostic and Predictive Biomarkers for Endometrial Cancer in Clinical Practice: Recommendations/Proposal from the Italian Study Group, Frontiers in Oncology, 12, 2022. Crossref

  37. Köstler Wolfgang J., Schwab Barbara, Singer Christian F., Neumann Rainer, Rücklinger Ernst, Brodowicz Thomas, Tomek Sandra, Niedermayr Monika, Hejna Michael, Steger Günther G., Krainer Michael, Wiltschke Christoph, Zielinski Christoph C., Monitoring of Serum Her-2/ neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer, Clinical Cancer Research, 10, 5, 2004. Crossref

  38. Murphy Amanda J., Hughes Caroline A., Barrett Ciara, Magee Hilary, Loftus Barbara, O'Leary John J., Sheils Orla, Low-Level TOP2A Amplification in Prostate Cancer Is Associated with HER2 Duplication, Androgen Resistance, and Decreased Survival, Cancer Research, 67, 6, 2007. Crossref

  39. Biam Roody S., Robichaud Philippe-Pierre, Mbarik Maroua, Pineau Paskale, Surette Marc E., Loss of detection of fatty acid-metabolizing proteins in Western blot analyses – Impact of sample heating, Biochemical and Biophysical Research Communications, 607, 2022. Crossref

  40. M Vijayalakshmi , Thilagavathy N Sharmila, Rani K , Role of HER2/neu expression in premalignant and malignant lesions of uterine cervix, Indian Journal of Pathology and Oncology, 9, 3, 2022. Crossref

Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集 価格及び購読のポリシー Begell House 連絡先 Language English 中文 Русский Português German French Spain